SCHEMBL6473173

SCHEMBL6473173

CCOC(=O)C(=Cc1ccc(-c2cccc(CNC)c2)cc1)CC(=O)OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 3/20 0.41
DHODH Q02127 2/20 0.40
HTR7 P34969 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
NR1H4 Q96RI1 1/20 0.38
EPHX2 P34913 3/20 0.38
PPID Q08752 1/20 0.37
PTGS2 P35354 1/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
S1PR4 O95977 1/20 0.36
S1PR1 P21453 1/20 0.36
MAPK1 P28482 1/20 0.36
BCL2 P10415 1/20 0.36
SYK P43405 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6473169 0.93 PRMT6 (0.42) PRMT6DHODHHTR7MEN1KMT2A
SCHEMBL6473177 0.93 PRMT6 (0.42) PRMT6DHODHHTR7MEN1KMT2A
SCHEMBL6531485 0.85 PPID (0.36) DHODHMEN1KMT2ANR1H4EPHX2
SCHEMBL6473078 0.79 AOC3 (0.41)
SCHEMBL6531486 0.77 PPID (0.37) DHODHEPHX2PPIDSYK
SCHEMBL6531479 0.77 PPID (0.37) DHODHEPHX2PPIDSYK
SCHEMBL6184145 0.77 PRMT6 (0.49) PRMT6HTR7EPHX2PTGS2CYP2C9
SCHEMBL6184148 0.77 PRMT6 (0.49) PRMT6HTR7EPHX2PTGS2CYP2C9
SCHEMBL6473073 0.75 EPHX2 (0.38) EPHX2PPIDLMNAMAPTCYP2C19
SCHEMBL6473082 0.75 EPHX2 (0.38) EPHX2PPIDLMNAMAPTCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD PRMT6 4002/4885DHODH 2385/4885HTR7 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.